437 related articles for article (PubMed ID: 32529893)
1. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
Walsh GM
Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
[TBL] [Abstract][Full Text] [Related]
2. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.
Walsh GM
Expert Rev Clin Immunol; 2017 Feb; 13(2):143-149. PubMed ID: 27459348
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
Walsh GM
Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
[TBL] [Abstract][Full Text] [Related]
4. Biological therapies for eosinophilic asthma.
Patel SS; Casale TB; Cardet JC
Expert Opin Biol Ther; 2018 Jul; 18(7):747-754. PubMed ID: 29938543
[TBL] [Abstract][Full Text] [Related]
5. Reslizumab in the treatment of severe eosinophilic asthma: an update.
Walsh GM
Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment.
Walsh GM
Adv Pharmacol; 2023; 98():31-54. PubMed ID: 37524491
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
8. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
9. Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.
Kupczyk M; Kuna P
Immunotherapy; 2018 Apr; 10(5):349-359. PubMed ID: 29359607
[TBL] [Abstract][Full Text] [Related]
10. Update on reslizumab for eosinophilic asthma.
Cardet JC; Israel E
Expert Opin Biol Ther; 2015; 15(10):1531-9. PubMed ID: 26372797
[TBL] [Abstract][Full Text] [Related]
11. Benralizumab for the treatment of asthma.
Saco TV; Pepper AN; Lockey RF
Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
[TBL] [Abstract][Full Text] [Related]
12. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
13. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of refractory asthma with antibodies].
Lommatzsch M
Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
16. Update on new biologics for intractable eosinophilic asthma: impact of reslizumab.
Sahota J; Robinson DS
Drug Des Devel Ther; 2018; 12():1173-1181. PubMed ID: 29780238
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab for eosinophilic severe asthma: recent studies.
Robinson DS; Kariyawasam HH
Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
19. Mepolizumab-based therapy in asthma: an update.
Walsh GM
Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
